NewLake Capital Partners, Inc. is a New York-based cannabis real estate investment trust (REIT) that acquires and leases industrial and retail properties to state-licensed cannabis operators. Founded in 2019, NLCP operates under a triple-net lease (NNN) structure where tenants bear all operating expenses including taxes, insurance, and maintenance. NLCP cannot list on major exchanges (NYSE, NASDAQ) due to U.S. federal law that still classifies cannabis as a Schedule I controlled substance, restricting NLCP to the OTCQX market. This structural limitation is both the primary risk and the primary opportunity — rescheduling or descheduling cannabis would be a transformational catalyst for the stock.

Portfolio Summary

Portfolio Dynamics: NLCP has built a concentrated portfolio of 32 NNN-leased cannabis properties across 12 states. 100% occupancy and long lease terms (14+ years avg) provide exceptional revenue visibility. The tenant base consists of multi-state operators (MSOs) — Curaleaf, AYR Wellness, PharmaCann, and TerrAscend are the largest. The primary credit risk is tenant financial health: cannabis operators are squeezed by 280E tax obligations, state licensing fees, and price compression in mature markets. NLCP carries minimal financial debt ($7.7M LT debt as of FY2024) — an unusual and positive feature for a REIT. Revenue has grown modestly: $27.5M in FY2021 → $50.5M in FY2025, with growth decelerating as the portfolio reaches stabilization. The key catalyst for re-rating is federal cannabis reform (SAFE Banking Act passage or DEA rescheduling to Schedule III).

Green = >10% above current price. Red = >10% below. Gold = within ±10%.

Log-linear trend fitted to full price history. ±1.5σ bands. Green shaded zone = bottom 25% of historical range — historically attractive entry.

Bull Case — What Has to Be True: The DEA completes rescheduling of cannabis to Schedule III (or Congress passes SAFE Act), allowing NLCP to list on NYSE/NASDAQ and attract institutional capital. This single event could re-rate the stock from 11% yield to 7-8% yield (standard industrial NNN REIT), implying a stock price of $21-$25. Major tenant MSOs stabilize financially as 280E tax burden reduces under Schedule III. NLCP expands portfolio with new properties in newly legalized states. Bull IV: $20.14 (+30% from current).

Bear Case — Real Risks: Federal reform continues to stall (Congress fails to act, DEA reverses). Major tenants (Curaleaf has $800M+ in debt, AYR has struggled financially) face distress and lease restructuring. NLCP is forced to cut the dividend to preserve capital. The cannabis retail market faces continued price compression — operators can't afford rent in a down cycle. OTC-only listing means no index inclusion, limiting the institutional buyer base permanently. Bear IV: $12.78 (-17.5% downside).

Base Case Assumptions: DPS maintained at $1.72/sh with 2% annual growth; portfolio 100% occupied; no major tenant defaults; cannabis reform debates continue without resolution; Ke = 12.5% (Rf 4.3% + beta 0.857 × ERP 5.5% = 9.0% + 1.5% cannabis risk + 2.0% OTC illiquidity premium). Base DDM IV: $15.92 (+2.7% above analyst PT of $15.50).

Verdict: At $15.50, NLCP is priced at fair value for what it is — a specialty REIT yielding 11.1% in a regulated market with binary reform optionality. The 11.1% yield is attractive if you believe the dividend is safe (we give it a WATCH rather than SAFE — thin margin above the FFO payout). The key asymmetry: cannabis reform would be worth $5-10/share upside; without reform, the stock drifts sideways on the yield. We rate NLCP Hold. Joseph holds 3,322 shares at $15.20 cost basis — essentially at cost. No action needed. If stock drops below $13, it becomes a Buy. Above $17 with no reform catalyst, trim toward target size.